Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

0.9935
-0.0665-6.27%
Pre-market: 1.010.0165+1.66%06:33 EDT
Volume:12.65M
Turnover:12.58M
Market Cap:336.32M
PE:-3.89
High:1.06
Open:1.05
Low:0.9800
Close:1.06
52wk High:2.73
52wk Low:0.9800
Shares:338.52M
Float Shares:327.56M
Volume Ratio:0.82
T/O Rate:3.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-20.31
PE(LYR):-4.40

Loading ...

Ocugen - to Initiate Ocu410 Phase 3 Trial in Q3 2026, Bla Filing Anticipated in 2028

THOMSON REUTERS
·
Jul 29

Ocugen Announces That the U.S. Food and Drug Administration Has Granted Ocu410 Regenerative Medicine Advanced Therapy (Rmat) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
Jul 29

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

GlobeNewswire
·
Jul 29

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Jul 28

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 25

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Jul 24

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 21

Ocugen Announces Special Shareholder Meeting

Reuters
·
Jul 21

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Jul 17

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 14

Ocugen inks OCU400 licensing deal for MENA

TIPRANKS
·
Jul 14

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical

TIPRANKS
·
Jul 13

Ocugen Rises on Mideast Licensing Deal for Experimental Blindness Gene Therapy

Reuters
·
Jul 13

Ocugen - to Receive up to $4 Mln in Upfront and Near-term Milestone Payments

THOMSON REUTERS
·
Jul 13

Ocugen - Signs Binding Term Sheet for Exclusive Ocu400 License in Mena Region

THOMSON REUTERS
·
Jul 13

Ocugen - Entitled to up to $255 Mln in Sales Milestones and 22% Royalty on Net Sales

THOMSON REUTERS
·
Jul 13

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

GlobeNewswire
·
Jul 13

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Jul 10

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 07